Personal Account
Personal Account
- Main /
- Company /
- boundless-bio
Boundless Bio
Biotechnology
Company websiteBOLD.NASDAQ
us
2018
72
3/31/2024
About
A company operating in the field of oncology and currently in the clinical trial phase is seeking to establish a new paradigm in cancer treatment. It focuses on patients with an increased number of oncogenes, targeting extrachromosomal DNA (ecDNA), which is one of the causes of oncogene amplification, found in more than 14% of cancer patients.
The company is registered in Delaware.
Headquarters
9880 Campus Point Drive, Suite 120 San Diego, CA 92121
Team
Zachary Hornby - CEO, President, and Director
Neil Abdollahian - Chief Business Officer
Amy Berkley, Ph.D. - Vice President, Program Team Leadership and Strategic Alliances
Financial information
| Year Ended December 31, |
||||||||
| 2022 | 2023 | |||||||
| (in thousands, except per share data) |
|
|
||||||
|
Statements of Operations Data: |
||||||||
|
Operating expenses: |
||||||||
|
Research and development |
$ | 37,159 | $ | 42,637 | ||||
|
General and administrative |
9,310 | 12,159 | ||||||
|
|
|
|
|
|||||
|
Total operating expenses |
46,469 | 54,796 | ||||||
|
|
|
|
|
|||||
|
Loss from operations |
(46,469 | ) | (54,796 | ) | ||||
|
Other income (expense), net: |
||||||||
|
Interest income |
668 | 5,282 | ||||||
|
Other income (expense) |
(100 | ) | 80 | |||||
|
|
|
|
|
|||||
|
Total other income (expense), net |
568 | 5,362 | ||||||
|
|
|
|
|
|||||
|
Net loss |
$ | (45,901 | ) | $ | (49,434 | ) | ||
|
|
|
|
|
|||||
|
Net loss per common share, basic and diluted(1) |
$ | (2.14 | ) | $ | (2.08 | ) | ||
|
|
|
|
|
|||||
|
Weighted-average shares used in net loss per common share calculation, basic and diluted(1) |
21,406 | 23,713 | ||||||
|
|
|
|
|
|||||
|
Pro forma net loss per common share, basic and diluted (unaudited)(2) |
$ | (0.18 | ) | |||||
|
|
|
|||||||
|
Pro forma weighted-average shares used in pro forma net loss per common share calculation, basic and diluted (unaudited)(2) |
272,811 | |||||||
|
|
|
|||||||
Underwriters
Goldman Sachs, Leerink Partners, Piper Sandler, Guggenheim Securities